[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP3840670B2 - Fat transfusion for diabetics - Google Patents

Fat transfusion for diabetics Download PDF

Info

Publication number
JP3840670B2
JP3840670B2 JP03156195A JP3156195A JP3840670B2 JP 3840670 B2 JP3840670 B2 JP 3840670B2 JP 03156195 A JP03156195 A JP 03156195A JP 3156195 A JP3156195 A JP 3156195A JP 3840670 B2 JP3840670 B2 JP 3840670B2
Authority
JP
Japan
Prior art keywords
fat
acid
infusion
oil
linolenic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP03156195A
Other languages
Japanese (ja)
Other versions
JPH08198749A (en
Inventor
明良 池田
賢一 乾
幸史 國場
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP03156195A priority Critical patent/JP3840670B2/en
Publication of JPH08198749A publication Critical patent/JPH08198749A/en
Application granted granted Critical
Publication of JP3840670B2 publication Critical patent/JP3840670B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【0001】
【産業上の利用分野】
本発明は、新規な糖尿病患者用の静注用脂肪輸液剤に関するものである。
【0002】
【従来の技術】
糖尿病時には糖の利用性が低下するため、エネルギー源として脂肪の適用が考えられる。従来、経静脈栄養において必須脂肪酸およびエネルギー補給にはn−6系必須脂肪酸であるリノール酸を多量に含有する植物油が用いられている。前記植物油のひとつとしてダイズ油乳剤が挙げられるが、その主な構成脂肪酸であるリノール酸のエネルギー産生効率に比べ、α−リノレン酸のそれは明らかに高いことが知られている。ところが、α−リノレン酸を主成分とする脂肪輸液剤は未だ広く利用されるに至っていない。
【0003】
他方、糖尿病においては血管障害が多発し、その発症および進展に血栓形成が重要な因子となっている。トロンボキサンA2は強力な血小板凝集作用および血管収縮作用を有しており、トロンボキサンA2産生が亢進した状態になれば血栓が形成されやすくなる。糖尿病ではアラキドン酸からのトロンボキサンA2産生が亢進しており、アラキドン酸の前駆体であるリノール酸を多量に含む油脂の投与には疑問がもたれる。一方、n−3系脂肪酸であるα−リノレン酸はリノール酸代謝に拮抗しアラキドン酸の生成を抑制するのみでなく、アラキドン酸からのエイコサノイドの産生も抑制することが知られている。
【0004】
これまでn−3系脂肪酸の糖尿病に対する効果は、主に魚油あるいは魚油濃縮物を経口投与して検討されている。糖利用能を上昇させるとの報告(Popp-Snijders C. et al. Diab. Res., 4, 141-147, 1987、Storlien, L.H. et al. Science, 237, 885-887, 1987)がある一方、耐糖能を悪化させるとの報告(Kasim S.E. et al. J. Clin. Endcrinol. Metab., 67, 1-5, 1988、Borkman M. et al. Diabetes, 38, 1314-1319, 1989.、Friday K.E. et al. Diabetes Care, 12, 276-281, 1989)もあり、一定の見解が得られていない。これは魚油にはn−3系脂肪酸とともに飽和およびモノ不飽和脂肪酸も多く含まれることが、効果の判定をあいまいにしていると考えられる。一方、純粋なエイコサペンタエン酸を経口投与した場合には、耐糖能の悪化を認めない(角 誠二郎ほか, Ther. Res., 13, 358-367, 1992)ことや、ドコサヘキサエン酸のエマルジョンは血糖値を低下させる(Hamazaki, T. et al. Ann. N. Y. Acad. Sci., 683, 207-212, 1993)などの報告がある。
また特開昭60-248610号公報によれば、n−3系多価不飽和脂肪酸を含む油脂、例えば魚油またはそのエステルの経口投与は、糖尿病時の赤血球膜流動性を増し合併症の予防あるいは治療に有効である旨が記載されているが、栄養改善については確認されていない。
【0005】
また脂肪分中のα−リノレン酸エチルエステルあるいはトリグリセリド含量を10〜50%とした脂肪輸液剤(特公平4-21645号公報)やα−リノレン酸含有精製植物油(シソ油、エゴマ油あるいはアマニ油)と大豆油を重量比で1:4〜4:1に混合した脂肪輸液剤(特開平4-342534号公報)、精製エゴマ油を素材とした脂肪輸液(特開平5-39217号公報)が提案されている。しかし、これらの脂肪輸液剤の糖尿病時の効果については確認されていない。
【0006】
【発明が解決しようとする課題】
従来のリノール酸含量の多い脂肪輸液およびα−リノレン酸含有精製植物油を配合した脂肪輸液剤はいずれも栄養補給を主たる目的としたものである。また特公平4-21645号公報によればα−リノレン酸を高濃度に含む脂肪輸液剤は抗血栓性製剤としても有用であると示されているが、糖尿病時における栄養補給、脂肪酸代謝の異常およびエイコサノイド産生異常の改善については検討されていない。
【0007】
従って本発明は、糖尿病時における脂肪酸代謝の異常および病態を生理的代謝を介して改善し、また必須脂肪酸を補給しつつエネルギー素材として良好な糖尿病患者用の脂肪輸液剤を提供することにある。
【0008】
【課題を解決するための手段】
本発明者らは糖尿病における脂肪酸代謝の変動および病態像の軽減について研究を重ねた結果、α−リノレン酸を高濃度含有する脂肪輸液が糖尿病時の脂肪酸代謝の改善を介してエイコサノイド産生を良好に保ち、栄養状態を良好にせしめること、またその効果は油脂成分としてα−リノレン酸を多く含有する精製エゴマ油でなければ発現しないことを見い出し、これに基づいて本発明を完成した。
【0009】
すなわち、本発明は油脂の構成脂肪酸であるリノール酸とα−リノレン酸について、遊離酸として計算したリノール酸に対するα−リノレン酸の重量比が2.5〜7.0である油脂を有効成分として含有する糖尿病患者用脂肪輸液剤であり、その好ましい実施態様としては、前記有効成分として、少なくとも精製エゴマ油を含んでなる油脂を、脂肪輸液剤中に5〜30w/v%含有する糖尿病患者用脂肪輸液剤が挙げられる。
【0010】
本発明の糖尿病用脂肪輸液剤に配合する油脂としては、精製エゴマ油および精製エゴマ油と各種の植物油を公知の方法で精製した精製植物油を混合したものが挙げられる。前記油脂は、その構成脂肪酸として、リノール酸含量に対するα−リノレン酸含量の遊離酸として計算された重量比が1:2.5〜1:7.0、好ましくは1:3.5〜1:5.5、より好ましくは1:4.0〜1:5.0になるよう調製して配合することができる。なお、前記精製エゴマ油としては、精製エゴマ油を加水分解反応に付して脂肪酸を遊離せしめた場合に、遊離酸として計算されたα−リノレン酸の全遊離酸中に占める割合が51〜70重量%であるものが好適に使用できる。
【0011】
また、本発明の糖尿病患者用脂肪輸液剤には、従来より用いられている卵黄レシチンや水添大豆レシチン等の乳化剤、グリセリン、トコフェロール、また必要に応じて安定剤や等張化剤等の添加剤を加えることができる。本発明の脂肪輸液剤に配合される精製エゴマ油は、天然エゴマ油から得られる原油を脱ガム、脱酸、脱色、脱臭、脱ロウおよび活性炭処理工程からなるスチーム精製法により精製されたものを用いるとよい。前記精製は、天然のエゴマ油に含まれる人体に対して毒性を示す成分を除去するために行われるものである。さらに、前記精製エゴマ油は、トコフェロール含有量が31〜200mg/100gになるようにトコフェロールを添加したものが好適に使用できる。前記トコフェロール含有量の調製は、精製エゴマ油の経時的な安定性を高めるために行われ、更に脂肪輸液剤として投与された精製エゴマ油から生じる過酸化物を低減させるために行われるものである。
【0012】
本発明の糖尿病患者用脂肪輸液剤は、製造される脂肪輸液剤100容量部に対し精製エゴマ油をはじめとする植物油を5〜30重量%、好ましくは10〜20重量%含有させ、精製卵黄レシチンまたは水添ダイズレシチン1〜2重量%、グリセリン1.5〜3重量%を配合して公知の脂肪輸液剤の製造法により製造することができる。
【0013】
【実施例】
実施例1
精製エゴマ油100g(α−リノレン酸55.6g、リノール酸12.0g含有、リノール酸に対するα−リノレン酸の重量比(比率)4.6)に卵黄レシチン6.0g、グリセリン12.5gを加え、加温しながら激しく攪拌して溶解後、適当量の注射用蒸留水を加えてホモジナイザーで攪拌し、粗乳化液を調整した。この粗乳化液をさらにマイクロフルイダイザーM−110Y型(マイクロフルイダイザー社製)により高圧乳化させた後、注射用蒸留水を加えて全量を500mlとした。ここに得られた輸液をプラスチック製バックに充填、窒素置換後密栓した。これを高圧蒸気滅菌することにより、精製エゴマ油を20w/v%含有する糖尿病患者用脂肪輸液剤を調製した。
【0014】
実施例2
精製エゴマ油125g(α−リノレン酸69.5g、リノール酸15.0g含有、リノール酸とα−リノレン酸の重量比1:4.6)に卵黄レシチン6.0g,グリセリン12.5gを加え、実施例1と同様の操作にて精製エゴマ油を25w/v%含有する糖尿病患者用脂肪輸液剤を調製した。
【0015】
実施例3
精製エゴマ油150g(α−リノレン酸83.4g、リノール酸18.0g含有、リノール酸とα−リノレン酸の重量比1:4.6)に精製水添ダイズレシチン6.0g、グリセリン12.5gを加え、実施例1と同様の操作にて精製エゴマ油を30w/v%含有する糖尿病患者用脂肪輸液剤を調製した。
【0016】
実施例4
精製エゴマ油100g(α−リノレン酸55.6g、リノール酸12.0g含有、リノール酸とα−リノレン酸の重量比1:4.6)に卵黄レシチン12.0g、グリセリン25.0gを加え、実施例1と同様の操作にて全量1000ml中に精製エゴマ油を10w/v%含有する糖尿病患者用脂肪輸液剤を調製した。
【0017】
実施例5
精製エゴマ油97gと精製ダイズ油3gを配合した油脂(α−リノレン酸54.2g、リノール酸13.1g含有、リノール酸とα−リノレン酸の重量比1:4.1)に卵黄レシチン12.0g、グリセリン25.0gを加え、実施例1と同様の操作にて全量1000ml中に油脂を10w/v%含有する糖尿病患者用脂肪輸液剤を調製した。
【0018】
試験例
6週齢のSD系雄性ラットを用い糖尿病モデル(ストレプトゾトシンにより誘発したモデル)を作製し、1週間後に中心静脈にカテーテルを留置した後、脂肪輸液剤と等エネルギー量のブドウ糖液(対照1)、ダイズ油(油脂100g中α−リノレン酸7.3g、リノール酸50.2g、比率0.1)を主成分とした脂肪輸液剤(対照2)及び実施例1の脂肪輸液をそれぞれ投与した。なお、各試験群のラットの匹数は8〜9匹とし、被検液投与期間中は無脂肪食で飼育した。また参考のため健常ラット(6匹)および糖尿病ラット(7匹)の自由摂餌群を設けた。
被検液を7日間投与した後、栄養効果、血清リン脂質脂肪酸組成、血小板トロンボキサンA2産生量を測定した。
【0019】
表1および表2に示したごとく、体重増加量及び累積窒素出納は本発明の糖尿病患者用脂肪輸液剤において従来の脂肪輸液剤(対照2)に比較し明らかに高い値を示した。また表3に示したごとく、肝および腎機能指標に異常はみられなかった。すなわち、本発明の脂肪輸液剤は糖尿病時の栄養状態を良好に維持することが明らかになった。
【0020】
【表1】

Figure 0003840670
【0021】
【表2】
Figure 0003840670
【0022】
【表3】
Figure 0003840670
【0023】
表4に示したごとく、血漿インスリン濃度は本発明の糖尿病患者用脂肪輸液剤において従来の脂肪輸液剤(対照2)に比較し高い値を示した。
【0024】
【表4】
Figure 0003840670
【0025】
表5および表6に示したごとく、本発明の糖尿病患者用脂肪輸液剤は血清リン脂質のアラキドン酸を低下させ、エイコサペンタエン酸を上昇させるとともに血小板トロンボキサンA2産生量を低下させた。すなわち、本発明の糖尿病患者用脂肪輸液剤は、糖尿病時の脂肪酸代謝及びエイコサノイド産生を改善することが明らかとなった。
【0026】
【表5】
Figure 0003840670
【0027】
【表6】
Figure 0003840670
【0028】
【作用】
本発明の糖尿病患者用脂肪輸液剤は、糖尿病における生理的代謝を介して血栓性合併症を改善しうる。また病態時の栄養状態を改善する作用を有する。この効果は、従来のリノール酸の多い脂肪輸液剤、あるいはリノール酸含有量の多い油脂と混合した脂肪輸液剤では認められず、α−リノレン酸含有量の多い脂肪輸液剤でのみ認められる。
【0029】
【発明の効果】
本発明は、α−リノレン酸を高濃度含有する脂肪輸液剤であるため、高カロリー輸液療法あるいは低脂肪経腸栄養療法を施行時において糖尿病の合併症の予防および栄養状態の改善に対し優れた効果を期待することができる。[0001]
[Industrial application fields]
The present invention relates to a novel intravenous fat infusion for diabetic patients.
[0002]
[Prior art]
The use of fat is considered as an energy source because the availability of sugar decreases during diabetes. Conventionally, vegetable oil containing a large amount of linoleic acid, which is an n-6 essential fatty acid, has been used for supplementing essential fatty acids and energy in parenteral nutrition. One of the vegetable oils is a soybean oil emulsion, and it is known that α-linolenic acid is clearly higher than the energy production efficiency of linoleic acid, which is the main constituent fatty acid. However, fat transfusions mainly composed of α-linolenic acid have not yet been widely used.
[0003]
On the other hand, vascular disorders frequently occur in diabetes, and thrombus formation is an important factor for the onset and progression. Thromboxane A 2 has a strong platelet aggregation action and vasoconstriction action, and a thrombus tends to be formed if thromboxane A 2 production is enhanced. In diabetes, thromboxane A 2 production from arachidonic acid is enhanced, and there is doubt about administration of fats and oils containing a large amount of linoleic acid, which is a precursor of arachidonic acid. On the other hand, α-linolenic acid, which is an n-3 fatty acid, is known not only to antagonize linoleic acid metabolism and suppress the production of arachidonic acid, but also to suppress the production of eicosanoids from arachidonic acid.
[0004]
So far, the effect of n-3 fatty acids on diabetes has been studied mainly by oral administration of fish oil or fish oil concentrate. While there are reports that sugar utilization is increased (Popp-Snijders C. et al. Diab. Res., 4, 141-147, 1987, Stollien, LH et al. Science, 237, 885-887, 1987) , Reports of worsening glucose tolerance (Kasim SE et al. J. Clin. Endcrinol. Metab., 67, 1-5, 1988, Borkman M. et al. Diabetes, 38, 1314-1319, 1989., Friday KE et al. Diabetes Care, 12, 276-281, 1989), and certain opinions have not been obtained. This is thought to be because the fish oil contains a lot of saturated and monounsaturated fatty acids as well as n-3 fatty acids, which makes the determination of the effect ambiguous. On the other hand, when eicosapentaenoic acid is administered orally, glucose tolerance does not deteriorate (Seijiro Kado et al., Ther. Res., 13, 358-367, 1992). (Hamazaki, T. et al. Ann. NY Acad. Sci., 683, 207-212, 1993).
According to Japanese Patent Laid-Open No. 60-248610, oral administration of fats and oils containing n-3 polyunsaturated fatty acids, such as fish oil or esters thereof, increases erythrocyte membrane fluidity during diabetes and prevents complications or Although it is described that it is effective for treatment, nutritional improvement has not been confirmed.
[0005]
In addition, fat infusions containing 10 to 50% of α-linolenic acid ethyl ester or triglyceride in fat (Japanese Patent Publication No. 4-21645) and α-linolenic acid-containing refined vegetable oil (perilla oil, sesame oil or linseed oil) ) And soybean oil mixed in a weight ratio of 1: 4 to 4: 1 (Japanese Patent Laid-Open No. 4-342534), and fat infusion made of purified sesame oil (Japanese Patent Laid-Open No. 5-39217) Proposed. However, the effect of these fat infusions in diabetes has not been confirmed.
[0006]
[Problems to be solved by the invention]
Conventional fat infusions containing high linoleic acid content and α-linolenic acid-containing purified vegetable oils are mainly intended for nutritional supplementation. According to Japanese Patent Publication No. 4-21645, fat infusions containing α-linolenic acid at high concentrations are also useful as antithrombotic preparations. However, nutritional supplementation and abnormal fatty acid metabolism during diabetes Improvement of eicosanoid production abnormality has not been studied.
[0007]
Accordingly, it is an object of the present invention to provide a fat transfusion agent for diabetic patients that improves abnormalities and pathological conditions of fatty acid metabolism at the time of diabetes through physiological metabolism and is good as an energy material while supplementing essential fatty acids.
[0008]
[Means for Solving the Problems]
As a result of repeated research on changes in fatty acid metabolism and reduction of pathophysiology in diabetes, the present inventors have found that fat infusion containing high concentrations of α-linolenic acid improves eicosanoid production through improvement of fatty acid metabolism during diabetes. It was found that the nutritional state was maintained and the effect was good, and that the effect was not expressed unless it was a refined sesame oil containing a large amount of α-linolenic acid as an oil and fat component, and the present invention was completed based on this.
[0009]
That is, in the present invention, fats and oils having a weight ratio of α-linolenic acid to linoleic acid calculated as a free acid of linoleic acid and α-linolenic acid, which are constituent fatty acids of the fat and oil, are 2.5 to 7.0 as active ingredients. It is a fat infusion for diabetics, and a preferred embodiment thereof is for diabetics containing 5-30 w / v% of fat containing at least purified sesame oil as the active ingredient in the fat infusion. Examples include fat infusions.
[0010]
Examples of the fats and oils to be blended in the fat infusion for diabetes of the present invention include refined sesame oil and a mixture of refined sesame oil and refined vegetable oils obtained by purifying various vegetable oils by known methods. The fats and oils have a weight ratio calculated as free fatty acid of α-linolenic acid content to linoleic acid content as a constituent fatty acid of 1: 2.5 to 1: 7.0, preferably 1: 3.5 to 1: It can be prepared and blended so as to be 5.5, more preferably 1: 4.0 to 1: 5.0. In addition, as said refined sesame oil, when the refined sesame oil is subjected to a hydrolysis reaction to release a fatty acid, the proportion of α-linolenic acid calculated as a free acid in the total free acid is 51 to 70. What is weight% can be used conveniently.
[0011]
The fat infusion for diabetic patients of the present invention includes conventionally used emulsifiers such as egg yolk lecithin and hydrogenated soybean lecithin, glycerin, tocopherol, and if necessary, stabilizers, isotonic agents and the like. An agent can be added. The refined sesame oil blended in the fat infusion of the present invention is obtained by purifying crude oil obtained from natural sesame oil by a steam purification method comprising degumming, deoxidation, decolorization, deodorization, dewaxing and activated carbon treatment steps. Use it. The said refinement | purification is performed in order to remove the component which shows toxicity with respect to the human body contained in natural sesame oil. Furthermore, the said refined sesame oil can use suitably what added the tocopherol so that tocopherol content might be 31-200 mg / 100g. The preparation of the tocopherol content is performed to increase the stability of the refined sesame oil over time, and further to reduce the peroxide generated from the refined sesame oil administered as a fat infusion. .
[0012]
The fat infusion for diabetic patients of the present invention contains 5 to 30% by weight, preferably 10 to 20% by weight of vegetable oil including refined sesame oil, based on 100 parts by volume of the fat infusion to be produced, and purified egg yolk lecithin Alternatively, it can be produced by blending 1 to 2% by weight of hydrogenated soybean lecithin and 1.5 to 3% by weight of glycerin by a known fat infusion preparation method.
[0013]
【Example】
Example 1
Add egg yolk lecithin 6.0 g and glycerin 12.5 g to 100 g of purified sesame oil (containing 55.6 g of α-linolenic acid, 12.0 g of linoleic acid, weight ratio (ratio) of α-linolenic acid to linoleic acid 4.6). Then, after stirring and dissolving vigorously while heating, an appropriate amount of distilled water for injection was added and stirred with a homogenizer to prepare a crude emulsion. This crude emulsion was further emulsified under high pressure by a microfluidizer M-110Y type (manufactured by Microfluidizer), and distilled water for injection was added to make the total volume 500 ml. The infusion solution obtained here was filled in a plastic bag, purged with nitrogen and sealed. This was autoclaved to prepare a fat infusion for diabetic patients containing 20 w / v% of purified sesame oil.
[0014]
Example 2
To 125 g of purified sesame oil (69.5 g of α-linolenic acid, 15.0 g of linoleic acid, weight ratio of linoleic acid to α-linolenic acid 1: 4.6) was added 6.0 g of egg yolk lecithin and 12.5 g of glycerin, A fat infusion for diabetic patients containing 25 w / v% refined sesame oil was prepared in the same manner as in Example 1.
[0015]
Example 3
Purified hydrogenated soybean lecithin 6.0 g, refined sesame oil 150 g (containing 83.4 g of α-linolenic acid, 18.0 g of linoleic acid, weight ratio of linoleic acid to α-linolenic acid 1: 4.6 g), 12.5 g of glycerin Then, a fat infusion for diabetic patients containing 30 w / v% refined sesame oil was prepared in the same manner as in Example 1.
[0016]
Example 4
To 100 g of purified sesame oil (containing 55.6 g of α-linolenic acid, 12.0 g of linoleic acid, weight ratio of linoleic acid to α-linolenic acid 1: 4.6), 12.0 g of egg yolk lecithin and 25.0 g of glycerin were added, A fat infusion for diabetic patients containing 10 w / v% of purified sesame oil in a total volume of 1000 ml was prepared in the same manner as in Example 1.
[0017]
Example 5
An oil containing 97 g of purified sesame oil and 3 g of purified soybean oil (containing 54.2 g of α-linolenic acid and 13.1 g of linoleic acid, weight ratio of linoleic acid to α-linolenic acid 1: 4.1) and egg yolk lecithin 12. 0 g and 25.0 g of glycerin were added, and a fat infusion solution for diabetic patients containing 10 w / v% of fats and oils in a total amount of 1000 ml was prepared in the same manner as in Example 1.
[0018]
Test Example A diabetic model (model induced by streptozotocin) was prepared using 6-week-old SD male rats, and after 1 week, a catheter was placed in the central vein, and then a glucose solution having the same energy amount as that of the fat infusion (control 1). ), A fat infusion agent (control 2) mainly composed of soybean oil (7.3 g of α-linolenic acid, 50.2 g of linoleic acid in 100 g of fat and oil, ratio 0.1) and the fat infusion of Example 1 were administered, respectively. . In addition, the number of rats in each test group was 8-9, and was bred on a fat-free diet during the test liquid administration period. For reference, a free feeding group of healthy rats (6 animals) and diabetic rats (7 animals) was provided.
After administration of the test solution for 7 days, nutritional effects, serum phospholipid fatty acid composition, and platelet thromboxane A 2 production were measured.
[0019]
As shown in Tables 1 and 2, the weight gain and cumulative nitrogen balance were clearly higher in the fat transfusion for diabetic patients of the present invention than in the conventional fat transfusion (control 2). Further, as shown in Table 3, no abnormality was observed in the liver and kidney function indicators. That is, it became clear that the fat transfusion agent of the present invention satisfactorily maintained the nutritional state during diabetes.
[0020]
[Table 1]
Figure 0003840670
[0021]
[Table 2]
Figure 0003840670
[0022]
[Table 3]
Figure 0003840670
[0023]
As shown in Table 4, the plasma insulin concentration was higher in the fat infusion for diabetic patients of the present invention than in the conventional fat infusion (Control 2).
[0024]
[Table 4]
Figure 0003840670
[0025]
As shown in Tables 5 and 6, the fat infusion for diabetic patients of the present invention decreased serum phospholipid arachidonic acid, increased eicosapentaenoic acid and decreased platelet thromboxane A 2 production. That is, it has been clarified that the fat infusion for diabetic patients of the present invention improves fatty acid metabolism and eicosanoid production during diabetes.
[0026]
[Table 5]
Figure 0003840670
[0027]
[Table 6]
Figure 0003840670
[0028]
[Action]
The fat infusion for diabetic patients of the present invention can improve thrombotic complications through physiological metabolism in diabetes. Moreover, it has the effect | action which improves the nutritional state at the time of a disease state. This effect is not observed in conventional fat infusions containing a large amount of linoleic acid or fat infusions mixed with oils and fats having a high content of linoleic acid, but only in fat infusions containing a large amount of α-linolenic acid.
[0029]
【The invention's effect】
Since the present invention is a fat infusion containing a high concentration of α-linolenic acid, it is excellent for prevention of diabetic complications and improvement of nutritional status during high calorie infusion therapy or low fat enteral nutrition therapy. The effect can be expected.

Claims (2)

油脂の構成脂肪酸であるリノール酸とα−リノレン酸について、遊離酸として計算したリノール酸に対するα−リノレン酸の重量比が2.5〜7.0である油脂であって、少なくとも精製エゴマ油を含んでなる油脂を有効成分として5〜30w/v%含有する糖尿病合併症としての腎機能低下の改善用脂肪輸液剤。  Fats and oils having a weight ratio of α-linolenic acid to linoleic acid calculated as a free acid of linoleic acid and α-linolenic acid, which are constituent fatty acids of fat and oil, is 2.5 to 7.0, and at least purified sesame oil A fat infusion for improving reduction of renal function as a diabetic complication, comprising 5 to 30% w / v as an active ingredient. 高カロリー輸液療法あるいは低脂肪経腸栄養療法の施行時に使用されるものである請求項1に記載の糖尿病合併症としての腎機能低下の改善用脂肪輸液剤。  The fat infusion for improving renal function decline as a diabetic complication according to claim 1, which is used at the time of performing high calorie infusion therapy or low fat enteral nutrition therapy.
JP03156195A 1995-01-27 1995-01-27 Fat transfusion for diabetics Expired - Fee Related JP3840670B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP03156195A JP3840670B2 (en) 1995-01-27 1995-01-27 Fat transfusion for diabetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03156195A JP3840670B2 (en) 1995-01-27 1995-01-27 Fat transfusion for diabetics

Publications (2)

Publication Number Publication Date
JPH08198749A JPH08198749A (en) 1996-08-06
JP3840670B2 true JP3840670B2 (en) 2006-11-01

Family

ID=12334597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP03156195A Expired - Fee Related JP3840670B2 (en) 1995-01-27 1995-01-27 Fat transfusion for diabetics

Country Status (1)

Country Link
JP (1) JP3840670B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
DE10345401A1 (en) * 2003-09-30 2005-04-28 Bioplanta Arzneimittel Gmbh Use of alpha-linolenic acid and alpha-linolenic acid-containing vegetable oils

Also Published As

Publication number Publication date
JPH08198749A (en) 1996-08-06

Similar Documents

Publication Publication Date Title
JP2810916B2 (en) Pharmaceutical compositions containing fatty acids
JP2796838B2 (en) Method of manufacturing a medicament for the treatment of schizophrenia and / or associated tardive movement disorder
US5589508A (en) Use of an emulsion to prepare an intravensously administered medicament for treating skin diseases
AU709867B2 (en) Fatty acid treatment
Behrman et al. Blood lipid alterations in infants receiving intravenous fat-free alimentation
CN1267085C (en) Modifying the fatty acid composition of cell membranes of organs and tissues
KR20030016306A (en) Therapeutic combinations of fatty acids
WO2007070307A2 (en) Intravenous essential fatty acid emulsion
JPH08500332A (en) Use of an emulsion for preparing a parenterally administered drug for the treatment of inflammatory diseases
JPS6296421A (en) Manufacture of preventive or therapeutic composition for diabetic neurotic disease and prevention or remedy therefor
EP1912638A2 (en) Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids
JP2021526511A (en) Parenteral nutrition
JPH07508720A (en) Monounsaturated fats as dietary supplements to minimize the effects of catabolic metabolic diseases
JPH06511384A (en) Nutrition for humans and animals
TWI749451B (en) Pharmaceutical composition comprising omega fatty acids, and infusion preparation comprising the same
JP3840670B2 (en) Fat transfusion for diabetics
JPH0465048B2 (en)
JP3132085B2 (en) Fat emulsion
Lerner et al. A fat emulsion for intravenous feeding.
JPH0615469B2 (en) Fat infusion
JP4473968B2 (en) Blood cell fluidity improver
JPH0692848A (en) Emulsion for treating diabetes
JPH0539217A (en) Fat transfusion solution containing refined perilla oil blended therein
Tweedle The use of fat emulsions in parenteral nutrition
JPH04342534A (en) Fat emulsion for intravenous injection enriched with n-3 polyvalent unsaturated fatty acid

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050621

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20050621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060124

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060418

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060731

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090818

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090818

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100818

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100818

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees